HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Deborah W Knapp Selected Research

Piroxicam (Feldene)

4/2016A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma.
10/2007Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder.
4/2007Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment.
2/2004Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs.
2/2003Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
6/2002Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs.
1/2002Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
1/2002Antitumor effects of piroxicam in spontaneous canine invasive urinary bladder cancer, a relevant model of human invasive bladder cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Deborah W Knapp Research Topics

Disease

32Neoplasms (Cancer)
11/2021 - 01/2002
24Urinary Bladder Neoplasms (Bladder Cancer)
01/2020 - 01/2002
18Transitional Cell Carcinoma
04/2018 - 01/2002
17Carcinoma (Carcinomatosis)
11/2021 - 01/2002
6Neoplasm Metastasis (Metastasis)
01/2019 - 01/2006
3Lymphoma (Lymphomas)
02/2014 - 06/2002
2Neutropenia
12/2018 - 01/2013
2Glioma (Gliomas)
08/2018 - 01/2018
2Thrombocytopenia (Thrombopenia)
08/2018 - 06/2018
2Breast Neoplasms (Breast Cancer)
01/2015 - 11/2004
2Squamous Cell Carcinoma of Head and Neck
04/2007 - 02/2004
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2021
1Papilloma (Papillomatosis)
11/2021
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
06/2018
1Urethral Obstruction
12/2012
1Infections
11/2004
1Melanoma (Melanoma, Malignant)
02/2004
1Obesity
01/2003
1Adenocarcinoma
01/2002

Drug/Important Bio-Agent (IBA)

8Piroxicam (Feldene)FDA LinkGeneric
04/2016 - 01/2002
7Biological ProductsIBA
01/2019 - 01/2012
5Cyclooxygenase InhibitorsIBA
04/2016 - 01/2002
4Complement System Proteins (Complement)IBA
11/2021 - 05/2009
4Phenobarbital (Luminal)FDA Link
01/2019 - 01/2015
4Pharmaceutical PreparationsIBA
12/2018 - 07/2005
3Folic Acid (Vitamin M)FDA LinkGeneric
12/2018 - 01/2013
3Chlorambucil (Leukeran)FDA Link
08/2018 - 06/2013
3Cyclooxygenase 2 (Cyclooxygenase-2)IBA
05/2010 - 01/2002
3Cisplatin (Platino)FDA LinkGeneric
10/2007 - 02/2003
2LipidsIBA
07/2018 - 11/2009
2Messenger RNA (mRNA)IBA
06/2018 - 01/2006
2HerbicidesIBA
07/2013 - 04/2004
2Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
10/2011 - 04/2008
2Celecoxib (Celebrex)FDA Link
05/2010 - 04/2008
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2010 - 01/2002
2Proteins (Proteins, Gene)FDA Link
05/2009 - 01/2006
2EphA2 ReceptorIBA
01/2006 - 11/2004
2LigandsIBA
01/2006 - 11/2004
2Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
02/2003 - 01/2002
2ProstaglandinsIBA
02/2003 - 01/2002
1VemurafenibIBA
11/2021
1MucinsIBA
01/2020
1Epidermal Growth Factor (EGF)IBA
01/2020
1anthrax toxin (anthrax lethal factor)IBA
01/2020
1Immunotoxins (Immunotoxin)IBA
01/2020
1RNA (Ribonucleic Acid)IBA
01/2019
1Immune Checkpoint ProteinsIBA
01/2019
1EC0531IBA
12/2018
1Fatty Acids (Saturated Fatty Acids)IBA
07/2018
1Monoclonal AntibodiesIBA
04/2018
1ErbB Receptors (EGF Receptor)IBA
04/2018
1ClaudinsIBA
01/2018
1Vinblastine (Vinblastine Sulfate)FDA Link
04/2016
1glycol-chitosanIBA
01/2016
1Peptides (Polypeptides)IBA
01/2016
1ferric oxide (iron oxide)IBA
01/2016
11,1'- (4,4,7,7- tetramethyl- 4,7- diazaundecamethylene)bis- 4- (3- methyl- 2,3- dihydro(benzo- 1,3- thiazole)- 2- methylidene)quinolinium (TOTO)IBA
01/2015
1AntibodiesIBA
02/2014
1Uroplakin IIIIBA
02/2013
1Biological FactorsIBA
02/2013
1EC0905IBA
01/2013
1nitinolIBA
12/2012
1Biomarkers (Surrogate Marker)IBA
11/2012
1Tumor Suppressor Protein p14ARF (p14ARF)IBA
01/2012
1DNA (Deoxyribonucleic Acid)IBA
01/2012
1prostaglandin-inositol cyclic phosphateIBA
12/2011
1deracoxibIBA
10/2011
1Nonesterified Fatty Acids (NEFA)IBA
11/2009
1Glycerophospholipids (Phosphoglycerides)IBA
11/2009
1Cadherins (E-Cadherin)IBA
01/2006
1EphrinsIBA
01/2006
1VitaminsIBA
07/2005
1Asparaginase (Elspar)FDA Link
07/2005
1Immunoglobulin G (IgG)IBA
11/2004
1AgarIBA
11/2004
1Angiogenesis Inducing Agents (Angiogenesis Factor)IBA
02/2003
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
02/2003
1Hormones (Hormone)IBA
01/2003
1Doxorubicin (Adriamycin)FDA LinkGeneric
06/2002
1PlatinumIBA
01/2002

Therapy/Procedure

18Therapeutics
11/2021 - 01/2002
8Drug Therapy (Chemotherapy)
01/2017 - 01/2002
2Immunotherapy
04/2018 - 01/2017
2Cystotomy
02/2013 - 08/2011
1Radiotherapy
10/2019
1Image-Guided Radiotherapy
10/2019
1Transcutaneous Electric Nerve Stimulation (TENS)
08/2015
1Oral Administration
06/2013
1Metronomic Administration
06/2013
1Stents
12/2012
1Semiconductor Lasers
04/2012
1Cystectomy
05/2010
1Combination Drug Therapy (Combination Chemotherapy)
07/2005